Organic & Biomolecular Chemistry · 2012 · 64 citations · 51 references
MedicineMedicinal ChemistryPharmacologyCancer PharmacologyDrug DiscoveryMolecular PharmacologyEnzyme InhibitionMitotic InhibitorsMolecular DockingAntiproliferative AgentsAntiproliferative Drug ActionBiological Evaluation ReportChemical Structure-activity RelationshipsG2 Phase RegulationMicrotubule Polymerization InhibitionPalladium-catalyzed Cross-couplingTubulin Polymerization Inhibitors
The synthesis and structure-activity relationships associated with a series of 1,1-diarylethylene tubulin polymerization inhibitors 3 and 4 are described. The key step for their preparation involves a palladium-catalyzed coupling of N-arylsulfonylhydrazones with aryl halides, thus providing flexible and convergent access to tri- and tetrasubstituted 1,1-diarylolefins 3 and 4 related to isocombretastatin A-4 (isoCA-4). These compounds have been evaluated for tubulin polymerization inhibitory activity as well as for cytotoxic activity. The most potent compounds are 1,1-diaryl-2-methoxyethylenes 4b, 4d and 4e having a trisubstituted double bond. They exhibited good antiproliferative activity against various human cancer cell lines (GI(50) = 8-80 nM). Compounds 4b and 4e strongly inhibited tubulin polymerization with IC(50) values of 2 and 3 μM, respectively, and induced cell cycle arrest in the G(2)/M phase in the K562 cell line. Docking studies in the colchicine binding site of tubulin allowed identification of residues most likely to interact with these inhibitors and explain their potent anti-tubulin activity.
51
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text